Insights

Gathering insights about Wint…

Similar companies to Wint

Wint Tech Stack

Wint uses 8 technology products and services including Twitter Ads, Linkedin Insight Tag, Cookiebot, and more. Explore Wint's tech stack below.

Twitter Ads
Advertising
Linkedin Insight Tag
Analytics
Cookiebot
Cookie Compliance
React
Javascript Frameworks
Trustpilot
Online Review Management
Java
Programming Languages
HSTS
Security
Google Tag Manager
Tag Management

Media & News

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has filed a new istaroxime PCT patent application entitled, “ISTAROXIME DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHMIA.”
Dec 09, 2024 | www.globenewswire.com
Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction
WARRINGTON, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has engaged New Growth Advisors (“NGA”), a leading life sciences consulting firm chosen by companies seeking discreet, conflict-free, and knowledgeable advice on complex M&A, asset sale, research, capital markets, and licensing transactions, as its strategic advisor to lead a process in respect of Windtree's cardiovascular portfolio, including a potential out-licensing transaction or asset sale. NGA has advised on transactions with an aggregate value approaching $400 million from 2023 through 2024.
Dec 04, 2024 | www.globenewswire.com
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates.
Nov 27, 2024 | www.globenewswire.com
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World
WARRINGTON, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company has completed national phase filings of patent applications around the world, including in the United States, Germany, France, Italy, Japan and China.
Oct 23, 2024 | www.globenewswire.com
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.
Oct 17, 2024 | www.globenewswire.com
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias
Sep 30, 2024 | www.globenewswire.com
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree's strategy and planned near-term milestones WARRINGTON, Pa., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it will hold a virtual Investor Day Presentation on October 1 at 3pm ET.
Sep 26, 2024 | www.globenewswire.com

Wint's Email Address Formats

Wint uses at least 1 format(s):

Wint Email Formats	Example	Percentage
First.Last@wint.se	John.Doe@wint.se	50%
First.Last@wint.se	John.Doe@wint.se	50%

Frequently Asked Questions

Where is Wint's headquarters located?

Wint's main headquarters is located at Drakegatan 10, Gothenburg, Västra Götaland County 41250, SE. The company has employees across 4 continents, including EuropeNorth AmericaAfrica.

What is Wint's stock symbol?

Wint is a publicly traded company; the company's stock symbol is FUR.

What is Wint's official website and social media links?

Wint's official website is wint.se and has social profiles on LinkedIn Crunchbase.

What is Wint's NAICS code?

Wint's NAICS code is 5412 - Accounting, Tax Preparation, Bookkeeping, and Payroll Services.

How many employees does Wint have currently?

As of October 2025, Wint has approximately 176 employees across 4 continents, including EuropeNorth AmericaAfrica. Key team members include Ceo: D. J.Cfo Wint: C. S.Chief Marketing Officer (cmo): U. A.. Explore Wint's employee directory with LeadIQ.

What industry does Wint belong to?

Wint operates in the Accounting industry.

What technology does Wint use?

Wint's tech stack includes Twitter AdsLinkedin Insight TagCookiebotReactTrustpilotJavaHSTSGoogle Tag Manager.

What is Wint's email format?

Wint's email format typically follows the pattern of First.Last@wint.se. Find more Wint email formats with LeadIQ.

When was Wint founded?

Wint was founded in 2011.

Wint

Q: What is Wint's official website and social media links?

Wint's official website is wint.se. Wint has social profiles on LinkedIn.

Q: How many employees does Wint have currently?

Wint has approximately 176 employees.

Q: What technology does Wint use?

Wint's tech stack includes LottieFiles, Lua, Varnish, Microsoft Clarity, Google Workspace.

AccountingSweden51-200 Employees

BUSINESS MADE FUN.
Ingen startar företag för att få jobba med ekonomiadministration. Den är ett nödvändigt ont som stjäl tid och resurser från kärnverksamheten. Med Wint är den tiden förbi. Mindre av det tråkiga, innebär mer av det roliga.

LÄGG TID PÅ DET SOM SPELAR ROLL.
Wint trollar bort ditt bokföringsarbete och frigör din tid. Små bolag slipper lägga resurser på extern ekonomiadministration. På större bolag kan ekonomer och ekonomiavdelningar ta mer strategiska och rådgivande roller.

SÄG NEJ TILL TRÅKIGA MÅSTEN.
Gå in på www.wint.se eller ring 010-19 90 500 så hjälper vi dig att komma igång.

Company Overview

Headquarters: Drakegatan 10, Gothenburg, Västra Götaland County 41250, SE
Website: wint.se
Stock Symbol: FUR
NAICS Code: 5412 - Accounting, Tax Preparation, Bookkeeping, and Payroll Services
Founded: 2011
Employees: 51-200

Media & News

Funding & Financials

$25M$50M
Wint's revenue is estimated to be in the range of $25M$50M

Funding & Financials

$25M$50M
Wint's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Wint

TaKaDu

MIYA

Syrinix Limited

Optimatics

Inflowmatix

DHI

Wint Tech Stack

Media & News

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

Wint's Email Address Formats

Frequently Asked Questions

Where is Wint's headquarters located?

What is Wint's stock symbol?

What is Wint's official website and social media links?

What is Wint's NAICS code?

How many employees does Wint have currently?

What industry does Wint belong to?

What technology does Wint use?

What is Wint's email format?

When was Wint founded?

Wint

Company Overview

Media & News

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?